Table 2.
Clinical inputs
| Variable | Value (%) | Source |
|---|---|---|
| Proportion of patients with incontinence | 60.00 | Nitti et al. [22]a |
| Percentage of patients switching treatment | 26.06 | Nazir et al. [17] |
| 12-month persistence (UK CPRD) | ||
| Mirabegron 50 mg | 37.70 | Astellas [16] |
| Fesoterodine 4/8 mg | 24.00 | Astellas [16] |
| Oxybutynin ER 5 mg | 17.20 | Astellas [16] |
| Oxybutynin IR 5 mg | 12.40 | Astellas [16] |
| Solifenacin 5/10 mg | 24.80 | Astellas [16] |
| Tolterodine ER 4 mg | 20.60 | Astellas [16] |
| Tolterodine IR 4 mg | 20.60 | Astellas [16] |
| Trospium ER 60 mg | 19.10 | Astellas [16] |
| Trospium IR 40 mg | 19.10 | Astellas [16] |
| Darifenacin 7.5 mg | 15.90 | Astellas [16] |
| Flavoxate 600 mg | 8.30 | Astellas [16] |
| General population mortality | 0.97 | ONS [18] |
CPRD Clinical Practice Research Datalink, ER extended release, IR immediate release, ONS Office for National Statistics
aA conservative estimate of 60% was applied to the model based on 65.7% of the total population who were reported to have urgency or mixed incontinence at baseline. All doses reported are the total dose per day